Bristol-Myers Squibb (BMY) Tops Q3 EPS by 14c, Offers FY20 and FY21 Guidance
Get Alerts BMY Hot Sheet
Price: $53.67 +0.79%
EPS Growth %: -21.0%
Financial Fact:
Net Sales: 4.92B
Today's EPS Names:
SHIM, KOD, HEWA, More
EPS Growth %: -21.0%
Financial Fact:
Net Sales: 4.92B
Today's EPS Names:
SHIM, KOD, HEWA, More
Join SI Premium – FREE
Bristol-Myers Squibb (NYSE: BMY) reported Q3 EPS of $1.63, $0.14 better than the analyst estimate of $1.49. Revenue for the quarter came in at $10.5 billion versus the consensus estimate of $10.33 billion.
GUIDANCE:
Bristol-Myers Squibb sees FY2020 EPS of $6.25-$6.35, versus the consensus of $6.27.
Bristol-Myers Squibb sees FY2021 EPS of $7.15-$7.45, versus the consensus of $7.39.
For earnings history and earnings-related data on Bristol-Myers Squibb (BMY) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Walgreens Boots Alliance (WBA) tops Q2 expectations, narrows full-year profit forecast
- MillerKnoll, Inc. (MLKN) Tops Q3 EPS by 1c; offers Q4 guidance
- China Automotive Systems (CAAS) Tops Q4 EPS by 24c ; Offers Guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!